Skip to main content

Table 2 Adverse events related to rituximab administration

From: Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

Timing of rituximab administration Number of patients who suffered from infusion reactions Number of patients who had no infusion reactions Total number of patients
With the first course of chemotherapy 14 15 29
With or after the second course of chemotherapy 4 23 27